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ABSTRACT 
Background: positron emission tomography (PET) is a valuable tool for the characterization 
of brain tumors in vivo; yet, few studies investigated the correlations between 11C-METH 
PET metrics and the clinico-radiological, histological and molecular features in patients 
affected by lower grade gliomas (LGGs). This observational study aimed at evaluating the 
relationships between carbon-11-methionine PET (11C-METH PET) metrics and structural 
MRI imaging with histo-molecular biomarkers in patients with LGGs candidate to surgery. 
Methods: 96 patients with pathologically proven LGGs (51 males, 45 females; age 44.1±13.7 
years; 45 grade II, 51 grade III), referred from March 2012 to January 2015 for tumor 
resection and submitted to pre-operative 11C-METH PET were enrolled. Semi-quantitative 
metrics for 11C-METH PET included Standard Uptake Value (SUV) max, SUV ratio to 
normal brain and metabolic tumor burden (MTB). PET semiquantitative metrics were 
analyzed and compared to MRI features, histological diagnosis, IDH-1/2 status and 1p/19q 
co-deletion. 
Results: Histological grade was associated with SUV Max (p=0.002), SUV ratio (p=0.011) 
and MTB (p.=0.001), with grade III lesions showing higher metrics. Among nonenhancing 
lesions on MRI, SUVmax (p=0.001), SUVratio (p=0.003) and MTB (p<0.001) were 
statistically different in grade II versus grade III. MRI lesion volume poorly correlated with 
MTB (r2=0.13). SUVmax and the SUVratio were higher (p<0.05) in IDH-1/2 wild-type 
lesions, while SUVratio was associated with the presence of 1p19q codeletion. 
Conclusions: 11C-METH PET metrics significantly correlate with histological grade and 
molecular profile. PET semiquantitative metrics can improve pre-surgical evaluation of 
LGGs and thus support the clinical decision-making.  
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INTRODUCTION 
World Health Organization (WHO) Grade II and III gliomas are tumors of the central 
nervous system (CNS) defined as lower-grade gliomas (LGGs) upon the clinical behavior and 
molecular stratification1–3. 
The updated WHO classification1 considers both histologic and molecular parameters as 
crucial for an integrated diagnosis. However, the coexistence of areas with different 
histological and biological characteristics in the same tumor can impair the possibility to 
reach a correct diagnosis. 
Conventional MRI is the standard modality for the pre-operative characterization of a 
primary brain tumor4,5, but LGGs often show absence of contrast enhancement in the early 
stages of progression, which can lead to an underestimation of tumor grading4,6. 
Positron emission tomography (PET) with radiolabelled amino-acids, like L-methyl-C11-
methionine (11C-METH), has been proven to be a valuable tool for the in vivo 
characterization of brain tumors. It has been shown that 11C-METH PET can differentiate 
gliomas7–11, it can provide prognostic information prior to surgery12–16, it can be used for 
radiation therapy planning17,18, and it has a high diagnostic accuracy in the detection of 
glioma recurrence19. Based upon these evidences, several international working groups, such 
as the Response Assessment in Neuro-Oncology (RANO) and the European Association of 
Neuro-oncology (EANO), recommended the additional use of amino acid PET imaging at 
every stage of brain tumor management20,21. 
Nevertheless, few studies evaluated the correlations between 11C-METH PET semi-
quantitative and qualitative metrics and the clinico-radiological, histological and molecular 
features in LGGs. The aim of this observational study was thus to characterize the 
relationships between 11C-METH PET metrics, conventional MRI parameters, histological 
and molecular factors and clinical features of patients undergoing surgical resection.  
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METHODS 
Patients’ population 
A series of 96 patients (51 males, 45 females; age 44.1±13.7 years) affected by LGGs (i.e. 
grade II and III), who underwent a craniotomy for tumor resection from March 2012 to 
January 2015, was analyzed in this observational cohort study (NCT02518061).  All patients 
had 11C-METH PET performed within 30 days before surgery, adequate tumor specimen 
following surgery and fully available clinical data including complete follow-up. 
Demographic profile and clinical-radiological features are reported in [Table 1]. Pathological 
diagnosis was performed according to according to the 2007 WHO Brain Tumor 
Classification22. This study was conducted with the approval (#1481) of the local ethic 
committee. 
11C-METH PET imaging 
Before surgery, all patients performed 11C-METH PET. The radiopharmaceutical, carrier-
free L-(methyl-11C)-methionine, was synthesized on-site using a General Electric TracerLab 
FXc synthesis module with the method previously described12. A total amount of 300-
500MBq, was administered in patients who had been fasting for at least 4 hours. Images were 
acquired 15 minutes later on a PET/CT tomograph, either a Biograph 6 LSO scanner 
(Siemens Medical Systems, Erlangen, Germany) or a Discovery 690 GE scanner (General 
Electric Healthcare, Waukesha, WI). CT attenuation-corrected 3D images were acquired for 
10min from the scalp to vertebra C3 level and images were subsequently reconstructed using 
an iterative reconstruction algorithm (OSEM) and displayed on GE Adw4.6 Workstation. 
Images were reconstructed and acquired in order to minimize differences in semi-quantitative 
evaluations related to the use of two different scanners.  
Data obtained by 11C-METH PET were analyzed by board-certified Nuclear Medicine 
physicians, and then revised based on a semi-quantitative scale. SUVmax (maximum 
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standardized uptake value), SUVratio and metabolic tumor burden (MTB) were considered as 
semi-quantitative parameters. SUVratio was obtained as the ratio between count rates 
determined in the region of interest (ROI) drawn in the tumor area with the highest uptake of 
11C-METH (SUVmax) and the count rates in a corresponding ROI drawn in the contralateral 
side. The values were corrected for injected activity and adjusted to the patient’s weight. 
Tumor volumes as found on PET were then delineated automatically with a dedicated 
workstation software package, the GE PETVCAR® (PET Volume Computer Assisted 
Reading), based on an estimated threshold weight of 50%. When needed, the volume was 
adjusted manually by visual thresholding. MTB was computed as the volume (expressed in 
cm3) delineated on 11C-METH PET by the ROI of the entire tumor extent. 
MRI Evaluation 
Volumetric MRI sequences were acquired preoperatively on all patients with a 3 Tesla MR 
scanner (Siemens Verio, Erlangen, Germany) on the day before surgery. Image evaluation 
was performed by a board-certified neuroradiologist, blinded to nuclear medicine data. 
Volumes were computed with iPlan Cranial 3.0 software suite (Brainlab, Munich, Germany) 
from T2-weighted hyperintense lesions on Fluid-attenuated-inversion-recovery (FLAIR) and 
from gadolinium enhancing T1-weighted lesions by manual delineation of the lesion borders 
on all involved slices. The pre-operative MRI dataset was coregistered with a CT head scan 
with 7 radiolucent fiducials and the 11-C-METH-PET with iPlan Cranial 3.0 software. The 
coregistered dataset was then available for image guidance during surgery on a 
neuronavigation platform (Brainlab Curve, Brainlab AG, Munich, Germany). 
Surgical Protocol 
All patients gave written informed consent to the surgical procedure. Surgery was performed 
with the aid of a multimodal electrophysiological monitoring and intraoperative stimulation 
mapping for motor and language functions, under asleep or awake anesthesia according to the 
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surgical indications23,24. An ultrasound machine (Prosound Alpha7, Hitachi Aloka Medical 
Ltd, Zurich, Switzerland) with a pre-calibrated multi-frequency (3.75-10 MHz) convex 
transducer footprint 20 mm was employed25. A rigid array with 3 optic references was 
mounted onto the transducer to have it integrated with the neuronavigation in order to guide 
the tissue sampling in vivo and to acknowledge possible shifting of the regions of interest.  
Pathological assessment 
Tumor grading was performed on slides in hematoxylin and eosin (H&E) according to WHO 
International Histological Classification of Tumors22. IDH-1 mutational analysis was 
conducted with immunohistochemistry using antibody to IDH R132H and wildtype cases 
were then validated by PCR reaction. 1p/19q co-deletion status was assessed with 
fluorescence in situ hybridization (FISH, Vysis 1p36/1q25 e 19q13/19p13): deletions of 1p 
and 19q were defined as 33% of tumor nuclei containing the LOH pattern. Table S1 reports 
the integrated diagnosis of the histopathological grading and the molecular profiles. The cell 
proliferation index was measured with immunohistochemistry using the MIB-1 antibody 
against Ki-67 protein. 
 
Statistical analyses 
An analysis of variance (ANOVA) was employed to explore the relationship among the PET 
metrics, as measured by semiquantitative parameters, and clinico-radiological features. 
Differences between rates were compared by the Chi square analysis. T-test was used to 
investigate differences between scanners (Siemens versus GE) for semiquantitative 
parameters. 
To investigate the relationship among metabolic metrics and the 3 molecular subgroups, the 
PET metrics were analyzed with ANOVA on the natural log of the dependent variable (the F-
test) and with a non-parametric Kruskal-Wallis test, due to distributional concerns. 
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For rank correlation, a Spearman’ correlation coefficient (rho) and linear regression test were 
used. Sensitivity, specificity and accuracy in characterizing grade (i.e. grade II vs III) was 
computed to estimate the power of each parameter to discriminate between the two grade 
classes. A study of optimal cut-off and of the accuracy was then using Receiver Operating 
Characteristic (ROC) curve analysis. A multivariate analysis was performed to test the 
relationship among PET semi-quantitative parameters and other radiological and molecular 
features.  
Statistical significance was set at p≤0.05 for each evaluation. 
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RESULTS 
PET semi-quantitative metrics and histological grade 
According to the WHO classification 2007, the distribution of brain tumors was as follows: 
26 grade II and 15 grade III oligodendrogliomas, 8 grade II and 22 grade III astrocytomas, 11 
grade II and 14 grade III oligoastrocytomas. Forty-eight tumors were newly diagnosed and 
treatments naive and 48 recurrent [Table 1]. 
The mean proliferative index, as measured by the MIB-1, was different between grades: i.e. 
3.0 for grade II and 13.3 for grade III (p<0.001). The proliferative index was related to 
SUVmax (F(1.92)=4.3, p=0.04), SUVratio (F(1.92)=4.2, p=0.04) and MTB (F(1.92)=9.8, 
p=0.002). 
Mean SUVmax was 3.5±1.7 (range 1.0-9.2), mean SUVratio 2.3±1.1 (range 1.1-8.3), mean 
MTB 33.13 (range 0.3-250.3). On T-test there was no difference between scanners for all 
semiquantitative parameters (p>0.05). When analyzed according to grade, a statistically 
significant difference was observed for SUVmax, SUVratio and MTB values between grade 
II and III. In particular, grade was related to SUVmax (F(1,94)=18.56, p<0.001), SUV ratio 
(F(1,94)=13.46, p<0.01 and MTB (F(1,94)=21.58, p<0.0001), with grade III lesions showing 
higher values for all metrics [Figure S1A-C].  
 
PET semi-quantitative metrics and MRI findings 
Sixty-nine patients had no enhancement, while 27 had a variable degree of enhancement on 
pre-operative MRI [Table 1]. Patients with contrast enhancement displayed statistically 
significant higher PET semiquantive values: SUVmax (F(1.94)=15.4, p<0.001), SUVratio 
(F(1.94)=12.4, p=0.001) and MTB (F(1.94)=6.9, p=0.01) were all related to the gadolinium 
enhancement.  
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Among nonenhancing LGGs [69 individuals, Table 2], SUVmax (p=0.001), SUVratio 
(p=0.003) and MTB (p<0.001) were all statistically different in grade II versus grade III 
lesions: SUVmax, SUVratio and MTB in nonenhancing grade-2 LGGs were on average, 
2.4±1.2, 1.7±0.6 and 7.1±0.9, respectively, compared to 3.6±1.4, 2.2±0.6and 28.8±1.0 for 
nonenhancing grade-3 LGGs. [Figure 1A-B] reports representative examples. 
The MRI lesion volume was correlated only to MTB (F(1.93)=9.9, p=0.002) but not 
SUVmax or SUVratio: however, the correlation between MRI volume and MTB was modest 
(r2=0.13) [Figure S2]. 
 
Accuracy, sensitivity and specificity of lesion characterization by PET and MRI 
Accuracy, sensitivity and specificity of the three PET measurements in discriminating 
between grade II and III was evaluated. Results showed an overall good accuracy, especially 
concerning specificity. Grade was statistically predicted by SUVmax (p<0.001), SUVratio 
(p=0.002) and also MTB (p<0.001). Optimal cut-off values were 2.7, 2.0 and 14.9 for 
SUVmax, SUVratio and MTB, respectively [Table 3]. 
To assess whether the combination of PET parameters and MRI features, namely the 
presence of contrast enhancement, is superior in the diagnostic accuracy to discriminate 
between grade II and III a further analysis was performed. In particular, the likelihood of a 
grade III lesion is higher when contrast enhancement co-exists with higher PET 
semiquantitative values; an overall gain in accuracy, sensitivity and specificity is observed, as 
reported in [Table 4] compared to MR or PET alone. 
 
PET semi-quantitative metrics and molecular features 
The relationships between metabolic parameters and molecular features was explored, 
constraining the analysis to newly diagnosed lesions. 
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Both SUVmax and the SUVratio were significantly higher (p<0.05) in IDH-1/2 wild-type 
lesions (no. 28) compared to mutated lesions (no. 20) [Figure 2A], while SUVratio was 
associated with the presence of 1p19q codeletion only, having 1p19q codeleted lesions a 
lower SUVratio [Figure 2B]. 
On multivariate analysis, SUVmax only was found significantly correlated with IDH status (p 
= 0.02), while other parameters, such as SUVratio, histological grade and presence of 
contrast enhancement, were not associated with the mutational status of IDH. 
A trend toward a correlation between PET semiquantitative metrics and the 3 molecular 
subgroups of the new WHO classification of 2016, i.e. IDH-1/2 mutated and 1p19 codeleted 
lesions, IDH-1/2 mutated and 1p19q not codeleted lesions and IDH-1/2 wild-type lesions, 
was evident, but not statistically significant [Figure 3]. 
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DISCUSSION 
LGGs display a variable prognosis, that is predicted by molecular factors3,21 in addition to 
clinical variables, such as age at diagnosis26, tumor volume27, speed of growth28 and extent of 
surgical resection27,29. The updated WHO classification of the CNS tumors of 2016 now 
includes both conventional histological parameters and molecular factors in an integrated 
diagnosis1. In particular, isocitrate dehydrogenases (IDH) status and codeletion of 
chromosome arms 1p and 19q (1p/19q codeletion), have been shown to capture the biologic 
characteristics of LGGs with greater sensitivity compared to histological classification 
alone30,  which can be hampered by both interobserver variability and sampling error during 
surgery. 
Positron emission tomography (PET) with radiolabelled amino-acids, like L-methyl-C11-
methionine (11C-METH), has been proven to be a valuable tool for the in vivo 
characterization of primary brain tumors31. 11C-METH PET can discriminate high from low 
grade gliomas7,9–12, provide prognostic information prior to surgery13–16,32 and be used for 
radiation therapy planning17,18; it also has a high diagnostic accuracy in the detection of 
glioma recurrence19. 
Based on a previous investigation12, the current study evaluated the additional benefit of 
metabolic imaging with 11C-METH-PET in the management of LGGs. Gliomas are 
heterogeneous tumors33–35, in whom the identification of the extent of infiltration and 
aggressive tumor components is relevant in planning surgery and performing sampling of the 
most representative tissue for a correct diagnosis. In this regard, conventional MRI has a 
limited definition of the heterogeneity and extension of gliomas; therefore, it has been 
questioned whether structural imaging only is able to appropriately guide the resection and 
the sampling or whether metabolic imaging should also be included, especially in case of 
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non-enhancing lesions36. The RANO working group20 and the EANO21 both recommended 
the use of amino acid PET as an additional tool for evaluating gliomas. 
To date, few studies investigated in LGGs the correlations of metabolic and structural MRI 
findings with molecular features and histological grade37,38. Among these studies, few only 
examined imaging findings in the context of the new WHO brain tumor classification12,15,39. 
Although the pathological diagnosis was still based on the 2007 WHO classification22, given 
the retrospective design, and this representing a limitation of the current observational study, 
a robust relationship among glioma grade and 11C-METH-PET semiquantitative metrics was 
found in several aspects: imaging with 11C-METH-PET can help in the distinction among 
nonenhancing gliomas on MRI between grade II and grade III tumors and higher values of 
SUVmax, SUVratio and MTB were significantly associated with Grade 3 lesions compared 
to Grade 2 lesions. 
No significant correlation was found between MRI volume and PET metrics [Figure S2]. 
This is not surprising because anaplastic areas, that can be detected by PET, co-exist with 
more differentiated areas without modifying the MRI volume in LGGs. The metabolic 
findings could thus be regarded as an additional non-invasive in vivo pre-operative biomarker 
of LGGs aggressiveness, along with an increase of lesion volume27 and speed of growth28. 
The combination of 11C-METH PET and conventional MRI enabled a more refined 
preoperative diagnosis. Diagnostic accuracy, sensitivity and, to a lower extent, specificity 
were improved when 11C-METH PET and conventional MRI were combined, reaching 
values of accuracy and specificity as high as 75% and 87%, respectively. The combination of 
the diagnostic yield of MRI with that of PET, in particular of the SUVmax, could be regarded 
as a promising approach for a better pre-treatment work-up of presumed LGGs [Figure 4], 
especially with an increasing use of hybrid MRI-PET facilities world-wide40. 
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In this study, we also found a significant association between IDH status and PET 
parameters, as IDH-1/2 wild-type lesions displayed a higher metabolic activity than IDH-1/2 
mutated LGGs in terms of SUVmax and SUVratio, while 1p19q codeleted lesions had a 
lower SUVratio. The latter finding, i.e. the relationship between the 1p19q loss of 
heterozygosity (LOH) and PET metrics can appear controversial when compared to earlier 
studies15, where LGGs with 1p19q codeletion displayed higher uptake of PET tracers. 
However, a more recent study found that 11C-METH-PET metrics were significantly higher 
in oligodendroglial lesions without 1p/19q deletion especially when the tumor to normal 
brain ratio was analyzed39, as in this study. This discrepancy could be explained by several 
factors, such as heterogeneity of different clinical cohorts and different percentages of true 
astrocytic and oligodendroglial lesions41. In addition, it could be argued that tumors without 
1p/19q deletion are less likely to have IDH1 mutation and this can lead to a more active 
metabolism than those with the deletions2,41.  
When we analyzed the 3 molecular subgroups we restricted the analysis to newly diagnosed 
lesions. IDH-1/2 wild-type lesions displayed a higher metabolic activity than IDH-
mutated/1p19 codeleted lesions and IDH-mutated/1p19q-not-codeleted lesions, as measured 
with SUVmax and SUVratio; however, the difference did not reach statistically significance. 
This could be due to either the small number of patients in each subgroup or the high relative 
fraction of IDH-wild type lesions. Further studies are thus needed to prove whether this 
interesting preliminary finding can be confirmed with a greater sample size and, hopefully a 
prospective design42. where the new WHO brain tumor classification can be considered ab 
initio. 
Some attention must be paid to acquisition protocols and reconstruction algorithms, 
particularly in the context of multiple scanner types or in multicentric settings, since the inter 
and intra-center comparability of PET data should be based on harmonized criteria. In 
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addition, when a robust correlation between imaging data and other patient’s pathological 
features is demonstrated, quantitative diagnostic findings could guide the choice of the site of 
tissue sampling, as it was done in the current study, where samples from hypermetabolic 
areas were sent separately for the histopathological diagnosis. This approach can reduce the 
errors in the histopathological evaluation, that are due to both sampling errors and 
interobserver variability43. 
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CONCLUSION 
Although retrospective, this observational study provided further evidence of the diagnostic 
power of 11C-MET PET in providing a refined pre-surgical evaluation of patients affected by 
presumed LGGs.  
The information gained on the metabolism of the lesions are of potential clinical impact for 
guiding treatment decisions44 in a patient-specific approach45, adding relevant clues about the 
site of tissue sampling for a proper integrated histomolecular diagnosis. 
PET imaging and the derived semiquantitative metrics can thus be considered relevant, along 
with other imaging techniques such as advanced MRI, to improve the non-invasive in-vivo 
characterization of LGGs and, ultimately, to promote an improved care and outcome of 
patients.  
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FIGURES CAPTION 
Figure 1. PET metrics in nonenhancing LGGs. 
The pre-operative T1-weighted after contrast injection (A), FLAIR (B) and 11C-METH-PET 
(C) scans of patient with a grade II, IDH-1 mutated and 1p19q codeleted oligoastrocytoma 
are reported (A-C). In this case, with no enhancement and a MRI volume of 30.2 cm3, 
SUVmax was 2.2, SUVratio was 1.7 and MTB was 15.1.  
Although having an overlapping MR phenotype (D,E,F) with no contrast enhancement and a 
MRI volume of 40.1 cm3, the PET metrics were higher (SUVmax 2.7, SUVratio 1.8, MTB 
29.2) in a patient with a final diagnosis of a grade III oligoastrocytoma, IDH-1/2 wild-type 
and with no 1p19q codeletion. PET also depicted a structural heterogeneity according to the 
metabotype, documenting several hypermetabolic foci within the lesion with a homogenous 
FLAIR MRI appearance. 
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Figure 2. Relationship between PET metrics and molecular markers. 
SUVmax and SUVratio, but not MTB, were statically significant higher in IDH wild type 
lesion compared to the mutated counterparts (A), while exclusively the SUVratio resulted 
lower in 1p19q codeleted LGGs (B). 
*p<0.01.  
 
n.s.: not statistically significant 
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Figure 3. PET metrics and molecular integrated diagnosis of LGGs 
Despite a trend can be noticed with SUVmax and SUVration, none of the PET metrics herein 
measured reached a statistically significant threshold, when LGGs of this cohort were 
partitioned according to the molecular features as recommended by the recently updated 
WHO brain tumor classification. 
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Figure 4. Multimodal pre-surgical characterization of LGGs  
The results of this study could be used to discuss the role of amminoacid PET in the pre-
surgical evaluation of LGGs. Following presentation, the diagnostic radiological work-up 
includes contrast-enhanced MRI, that provides relevant morphological data, such as lesion 
site, volume, signs of blood-brain-barrier breakdown as contrast enhancement and speed of 
growth, when serial scans are volumetrically analyzed.  
Amminoacid PET could integrate these data with semiquantitative metrics and a qualitative 
depiction of the structural heterogeneity. According to the metabolic activity measured from 
the lesion, this multimodal radiological evaluation could help identifying low- and high-
hazard lesions, being the latter those likely with a more aggressive behavior for their 
histopathology (i.e. grade III) and molecular status (IDH wild-type). 
This information could finally support clinical decision making, such as the timing of 
therapeutic intervention and the guidance of proper tissue sampling to minimize lesion under-
staging. In fact, high-hazard lesions should receive prompt treatment, while low-hazard lesion 
could undergo a close follow-up MRI scan to assess the speed of growth for a more refined 
tailoring of the treatment options.  
Table 1. Clinico-demographic characteristics  
 
Sex 
M/F     61/45   
Age      44.01±13.7 years 
Treatment naïve subjects  48 
Histology and Grade 
Grade II (no.)    45 
Oligodendroglioma   26 
Astrocytoma    8 
Oligoastrocytoma   11 
Grade III (no.)   51  
Anaplastic Oligodendroglioma 15 
Anaplastic Astrocytoma  22 
Anaplastic Oligoastrocytoma  14 
MRI Lesion volume   29.1 (232.1-1.1) cm3 
Lesion side 
R/L     46/50 
MRI enhancement 
Present    27 
Absent     69 
 
Table 1
Click here to download Table(s): 03_table 1.docx
Table 2. Non-enhancing LGGs on MRI and PET semi-quantitative parameters 
 
   SUVmax SUVratio MTB 
Grade II  2.4 ±1.2 1.7±0.6 7.1±0.9 
Grade III  3.6 ±1.4 2.2±0.6 28.8±1.0 
 
p-value  0.001  0.003  <0.001 
 
Mean values are reported. 
Table 2
Click here to download Table(s): 03_table 2.docx
Table 3. Discrimination of grade with PET, MR and Multimodal Metrics and identification 
of cut-off values in discriminating lower grade gliomas 
 
   Cut-off Accuracy Sensitivity Specificity 
SUVmax  2.7  67.8  55.6  78.4 
SUVratio  2.0  71.9  71.1  72.5 
MTB    14.9  67.8  64.4  70.6 
 
Gd enhancement N.A.  69.8  95.6  47.1 
 
 
Accuracy, sensitivity and specificity values are reported as percentages.  
N.A.:not applicable. 
Values of MR feature (presence of gadolinium, Gd, enhancement), obtained from this cohort, are 
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Table 4. Accuracy, sensitivity and specificity of multimodal characterization, combining 
PET semiquantitative metrics and MR features (gadolinium enhancement) 
     Accuracy  Sensitivity Specificity 
SUVmax    70.8  84.4  58.9 
SUVratio    70.8  86.7  56.9 
MTB     76.0  86.7  66.7 
 
Values are reported as percentages.  
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